LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells
Li X, Yamazaki T, He T, Alam M, Liu J, Trivett A, Sveinbjørnsson B, Rekdal Ø, Galluzzi L, Oppenheim J, Yang D. LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells. Frontiers In Immunology 2024, 15: 1332922. PMID: 38545099, PMCID: PMC10967226, DOI: 10.3389/fimmu.2024.1332922.Peer-Reviewed Original ResearchConceptsMaturation of dendritic cellsAnti-melanoma immunityDendritic cellsDamage-associated molecular patternsLTX-315LTX-315 treatmentAnticancer immunityDC maturationInduction of antigen-specific immunityMitogen-activated protein kinaseImmunogenic tumor cell deathMyeloid differentiation response geneTumor-infiltrating dendritic cellsTumor-specific immune responsesPromote DC maturationAntigen-specific immunityGeneration of tumor-specific immune responsesExperimental tumor modelsTumor cell deathNon-malignant cellsToll-like receptorsType 1 interferon productionIntracellular signaling pathwaysOncolytic peptideTumor model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply